A study has discovered that giving early breast cancer patients’ palbociclib alongside hormone treatment stopped tumor growth entirely.
Browsing: Disease Area > Breast
A study has demonstrated that women who function better at the beginning of the day than the end of the day could have a lower of risk breast cancer.
A major trial has demonstrated that fulvestrant–palbociclib combination therapy may prolong survival and delay the need for chemotherapy in women with advanced breast cancer.
In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2018.
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
Find out exclusive insights about the career of V. Craig Jordan who is considered the “father of tamoxifen” as well as details of the research areas he and his mentee Balkees Abderrahman are investigating.
Student aims to 3D print breast cancer tumors in an attempt to provide faster and more effective treatment for the disease.
Specific genes associated with triple-negative breast cancer risk have been identified by multigene hereditary cancer panel testing.
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.